Description
Can laminin-111 be used to treat Duchenne Muscular Dystrophy alone or in combination with myoblast transplantation?
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02012-04-01$535,740
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2012-04-01(start date) | $535,740 | — | Can laminin-111 be used to treat Duchenne Muscular Dystrophy alone or in combination with myoblast transplanta… |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2013-2014-Q2-00223 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $462,858 | FY2014 |
| 236-2012-2013-Q4-00677 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $160,000 | FY2014 |
| 236-2012-2013-Q2-00402 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $649,181 | FY2013 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2011-2012-Q4-00270 · retrieved 2026-11-14.